Newbridge Pharmaceuticals Joe Henein, President & CEO of Newbridge Pharmaceuticals, talks about the evolution of the company since his joining, what makes Newbridge Pharmaceuticals a unique partner within the industry, and expounds on the many possible options for the future of the company. Newbridge Pharmaceuticals is a unique company within the Middle…
R&D Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through risk mitigation. You founded Transition Therapeutics in 1998. What was the reasoning behind founding a biotech company focused on CNS…
diabetes Christine Marie D. Rosal, Country Manager of Novo Nordisk Pharmaceuticals (Philippines) gives a startling image of the current state of diabetes in the Philippines, the major reasons behind the soaring rates of diabetes and what the government along with companies such as Novo Nordisk can do to prevent a worsening…
Generics Executive Director, Teodoro B. Padilla, and Reiner W. Gloor, Adviser of Pharmaceutical & Healthcare Association of the Philippines (PHAP) argue that certain government initiatives, like discounted prices for senior citizens and students without financing them, put a perilous amount of pressure on the sector, and the necessity of raising awareness…
Pharmaceutical Industry Technology and Development Center (PITDC) The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development in Taiwan, and PITDC’s mission to bring the country’s domestic companies to the international level. What are your thoughts on…
International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA) General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved in the discussions with the government on how to rectify this growing problem. During our interviews, general managers heading IRPMA…
Array The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the key differences between the industry in Taiwan and Singapore. ASLAN is busy setting up a subsidiary in Taiwan. What attracted…
Biopharmaceutical Kevin Leshuk, Vice-President and General Manager of Celgene in Canada, offers his critique of the Canadian reimbursement and approval process as well as the advantages his affiliate enjoys in specialty pharma using Canada’s strong clinical base. What do Canadian biopharmaceutical companies offer as a competitive edge? I believe we have…
Biopharmaceutical Hervé Lilliu, General Manager of UCB Canada, describes Canada’s need to support the global pharma-ceutical industry rather than vice versa, and highlights examples of ways in which Canada’s slumbering R&D investment levels can be brought back to the country. What was your initial mandate upon arriving at UCB and what…
Biosimilars Jim Keon, Preisdent of CGPA, discusses the cost-saving benefits that generic drugs have offered Canada, and offers his insights into Canada’s intellectual property regime and the challenges of pricing in Canada. As a privileged witness to the evolution of the Canadian generic industry, what have been some of the defining…
Cardiology The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to bring CQDM to a more globally competitive level. You were appointed as CEO of CQDM about ten months ago. What…
See our Cookie Privacy Policy Here
